Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31536932 | 1.00 | HSD17B10 (0.48) | HSD17B10ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL2227750 | 0.79 | TSHR (0.48) | HSD17B10ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL10688254 | 0.76 | ALDH1A1 (0.46) | HSD17B10ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL1424323 | 0.76 | TSHR (0.45) | HSD17B10ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL351824 | 0.76 | TSHR (0.48) | HSD17B10ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL12275570 | 0.76 | TSHR (0.45) | HSD17B10ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL18000477 | 0.76 | TSHR (0.47) | HSD17B10ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL30945319 | 0.76 | TSHR (0.48) | HSD17B10ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL5313485 | 0.76 | ALDH1A1 (0.47) | HSD17B10ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL695579 | 0.76 | POLB (0.42) | HSD17B10ALDH1A1TDP1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059054-A1 | PROCESS FOR PREPARING (2S,4S,4'S,6S)-2-METHYL-6-(1-METHYL-1H-1,2,3-TRIAZOL-4-YL)-2',-(TRIELUOROMETHYL)-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO [2,3-C] PYRAN] -4'-OL | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-20 | — | — | WO | disclosed |
| US-12006316-B2 | 9H-pyrrolo-dipyridine derivatives | UCB Biopharma SRL (BE) | 2024-06-11 | — | — | US | disclosed |
| EP-4347032-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117813302-A | Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-111196804-B | TGF-beta R1 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-4146649-A1 | COMPOUNDS AS BCL-2 INHIBITORS | Fochon Pharmaceuticals, Ltd. (CN) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022256702-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220213103-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-07-07 | — | — | US | disclosed |
| US-11312716-B2 | 9H-pyrrolo-dipyridine derivatives | UCB Biopharma SRL | 2022-04-26 | — | — | US | disclosed |
| CN-114364664-A | BCAT modulation | 伊卡根有限责任公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-86107258-A | Pyridyl carbamide compound and on agricultural, using | — | 1987-05-27 | — | — | CN | disclosed |
| WO-1987002665-A1 | PYRIDINYLUREA COMPOUNDS AND AGRICULTURAL USES | FMC CORPORATION (US) | 1987-05-07 | — | — | WO | disclosed |
| US-4608380-A | HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-08-26 | — | — | US | disclosed |
| CN-85108132-A | Compounds process for production thereof | — | 1986-07-16 | — | — | CN | disclosed |
| EP-0181163-A2 | Heterocyclic phenoxy derivatives having an antihistamine H2 activity | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-05-14 | — | — | EP | disclosed |
| US-4587240-A | ANEMIA, IRON TOXICITY, 1-HYDORXYPYRIDONE-2 | NATIONAL RESEARCH DEVELOPMENT CORP. (GB) | 1986-05-06 | — | — | US | disclosed |
| EP-0143630-A2 | Chemical compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-06-05 | — | — | EP | disclosed |
| EP-0138421-A2 | Hydroxypyridone derivatives and pharmaceutical compositions containing them | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1985-04-24 | — | — | EP | disclosed |
| EP-0138420-A2 | Pharmaceutical compositions containing 1-hydroxypyrid-2-one derivatives | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1985-04-24 | — | — | EP | disclosed |
| US-4203988-A | ANTISECRETORY AGENTS | MERCK & CO., INC. (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213103-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | MAPT, PSEN1, PRNP | HSD17B10 3895/4885ALDH1A1 3567/4885TDP1 38/4885 |
| US-12006316-B2 | 9H-pyrrolo-dipyridine derivatives | MAPT, PSEN1, PRNP | HSD17B10 3895/4885ALDH1A1 3567/4885TDP1 38/4885 |
| US-11312716-B2 | 9H-pyrrolo-dipyridine derivatives | MAPT, PSEN1, PRNP | HSD17B10 3895/4885ALDH1A1 3567/4885TDP1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.